ExodusPoint Capital Management’s Heron Therapeutics HRTX Stock Holding History

ExodusPoint Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-38,699	Closed	-$85K	–	1683
2025 Q1	$85K	Buy	+38,699	New	+$75.1K	﹤0.01%	1353
2023 Q1	–	Sell	-423,898	Closed	-$1.06M	–	1913
2022 Q4	$1.06M	Buy	423,898 +10,286	+2%	+$33.1K	0.02%	914
2022 Q3	$1.75M	Buy	413,612 +281,359	+213%	+$1.1M	0.02%	859
2022 Q2	$369K	Sell	132,253 -35,249	-21%	-$142K	﹤0.01%	1457
2022 Q1	$958K	Buy	167,502 +100,039	+148%	+$732K	0.01%	1186
2021 Q4	$616K	Buy	+67,463	New	+$689K	0.01%	1290
2021 Q2	–	Sell	-26,627	Closed	-$432K	–	2547
2021 Q1	$432K	Buy	+26,627	New	+$475K	0.01%	1468
2020 Q4	–	Sell	-62,210	Closed	-$922K	–	2128
2020 Q3	$922K	Sell	62,210 -7,696	-11%	-$120K	0.02%	718
2020 Q2	$1.03M	Buy	+69,906	New	+$1.15M	0.03%	730

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ExodusPoint Capital Management's HRTX Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 38,699 shares — an estimated $85K sold.

ExodusPoint Capital Management first reported a position in HRTX in Q2 2020 and held it in 9 quarters. The position peaked at $1.75M in Q3 2022. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

ExodusPoint Capital Management reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 38,699 Heron Therapeutics shares in Q2 2025, an estimated $85K.
ExodusPoint Capital Management first reported a position in Heron Therapeutics in Q2 2020 and held it in 9 quarters.
ExodusPoint Capital Management's Heron Therapeutics position peaked at $1.75M in Q3 2022.
171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.